DiaMedica Therapeutics (DMAC) Accumulated Depreciation (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Accumulated Depreciation for 10 consecutive years, with $164000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Depreciation rose 28.12% year-over-year to $164000.0; the trailing twelve-month figure through Jun 2026 stood at $164000.0 (up 28.12% YoY), and the FY2025 full-year result was $150000.0, up 31.58% from the prior year.
• Accumulated Depreciation improved to $164000.0 in Q2 2026 per DMAC's latest filing, from $159000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $164000.0 in Q2 2026 and bottomed at $62000.0 in Q1 2022.
• Historically, Accumulated Depreciation has averaged $107444.4 across 5 years, with a median of $101500.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Accumulated Depreciation increased 6.19% in 2024, then surged 34.95% in 2025.
• Over 5 years, Accumulated Depreciation stood at $80000.0 in 2022, then increased by 25.0% to $100000.0 in 2023, then increased by 14.0% to $114000.0 in 2024, then surged by 31.58% to $150000.0 in 2025, then increased by 9.33% to $164000.0 in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $164000.0, $159000.0, and $150000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.